Screener
Krystal Biotech, Inc. KRYS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (see note 7) | ||
| Stockholders’ equity | ||
| Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2026 and December 31, 2025; 29,437 and 29,192 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 1,198,257 | 1,194,261 |
| Accumulated other comprehensive (loss) gain | (1,623) | 1,136 |
| Retained earnings | 80,095 | 24,163 |
| Total stockholders’ equity | 1,276,729 | 1,219,560 |
| Total liabilities and stockholders’ equity | $1,396,967 | $1,333,794 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s total equity?
- Krystal Biotech, Inc. (KRYS) reported total equity of $1.28B in Q1 2026.
- How has Krystal Biotech, Inc.'s total equity changed year-over-year?
- Krystal Biotech, Inc.'s total equity increased by 29.7% year-over-year, from $984.67M to $1.28B.
- What is the long-term trend for Krystal Biotech, Inc.'s total equity?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total equity has grown at a 33.1% compound annual growth rate (CAGR), from $292.08M to $1.22B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Krystal Biotech, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude